Strides Pharma Science Reports Strong Financial Growth and Improved Operational Metrics in March 2025 Results
Strides Pharma Science has announced its financial results for the quarter ending March 2025, highlighting significant growth in key metrics. Profit Before Tax reached Rs 121.82 crore, while Profit After Tax surged to Rs 104.26 crore. Net Sales and Operating Profit also achieved their highest levels in five quarters, indicating improved operational performance.
Strides Pharma Science has recently reported its financial results for the quarter ending March 2025, revealing notable developments within the company. The evaluation changes indicate a shift in the stock's score, which has adjusted to 21 from 24 over the past three months.The financial performance showcases significant growth in key metrics. Profit Before Tax less Other Income (PBT) reached Rs 121.82 crore, reflecting a substantial Year on Year (YoY) growth of 117.46%. Similarly, Profit After Tax (PAT) surged to Rs 104.26 crore, marking an impressive YoY increase of 301.8%. This quarter also saw the highest Operating Profit to Interest ratio in the last five quarters, recorded at 4.33 times, suggesting an improvement in the company's capacity to manage interest obligations.
Net Sales for the quarter hit Rs 1,190.39 crore, the highest in the last five quarters, while Operating Profit (PBDIT) also peaked at Rs 217.86 crore. These results indicate a positive trend in Strides Pharma's operational performance, reflecting the company's ongoing efforts to enhance its financial standing.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
